Lineage Cell Therapeutics (LCTX) News Today $0.68 -0.02 (-2.26%) Closing price 04:10 PM EasternExtended Trading$0.67 -0.01 (-1.89%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock LCTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period B. Riley Predicts Lineage Cell Therapeutics FY2029 EarningsLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Equities research analysts at B. Riley reduced their FY2029 earnings per share estimates for shares of Lineage Cell Therapeutics in a report issued on Friday, May 23rd. B. Riley analyst M. Mamtani now expects that the company wilMay 27 at 2:22 AM | marketbeat.comLineage Cell Therapeutics FY2029 EPS Lowered by B. RileyMay 27 at 2:13 AM | americanbankingnews.comLineage Cell Therapeutics at H.C. Wainwright: Strategic Insights on OpRegenMay 21, 2025 | investing.comJacobs Levy Equity Management Inc. Purchases Shares of 1,033,763 Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)Jacobs Levy Equity Management Inc. purchased a new stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,033May 20, 2025 | marketbeat.comComerica Bank Boosts Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)Comerica Bank grew its position in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 220.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 800,000 shares of theMay 18, 2025 | marketbeat.comLineage Cell Therapeutics Q2 EPS Lowered by HC WainwrightMay 18, 2025 | americanbankingnews.comLineage Cell Therapeutics’ Earnings Call Highlights Progress and ChallengesMay 15, 2025 | tipranks.comLineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYCMay 14, 2025 | businesswire.comLineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comLineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | businesswire.comExamining the Future: Lineage Cell Therapeutics's Earnings OutlookMay 12, 2025 | benzinga.comRG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025May 12, 2025 | businesswire.comDAFNA Capital Management LLC Raises Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)DAFNA Capital Management LLC raised its stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 85.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor ownedMay 10, 2025 | marketbeat.comAlyeska Investment Group L.P. Takes Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)Alyeska Investment Group L.P. purchased a new position in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,947,369 shares of the company's sMay 9, 2025 | marketbeat.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Purchased by Raffles Associates LPRaffles Associates LP increased its position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 21.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,492,088 shares of the comMay 3, 2025 | marketbeat.comLineage Cell Therapeutics (LCTX) to Release Earnings on ThursdayLineage Cell Therapeutics (NYSEAMERICAN:LCTX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-lineage-cell-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Bought by Renaissance Technologies LLCRenaissance Technologies LLC lifted its holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 1,058.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,283,072 shares of the company's stockMay 2, 2025 | marketbeat.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Sees Large Increase in Short InterestLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 26,640,000 shares, an increase of 19.2% from the March 15th total of 22,340,000 shares. Currently, 15.8% of the shares of the stock are sold short. Based on an average trading volume of 1,560,000 shares, the short-interest ratio is currently 17.1 days.April 23, 2025 | marketbeat.comLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor SymposiumApril 22, 2025 | businesswire.comLineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)April 21, 2025 | finance.yahoo.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 7.4% - Here's What HappenedLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Down 7.4% - What's Next?April 10, 2025 | marketbeat.comMaxim Group Reaffirms Their Buy Rating on Lineage Therap (LCTX)April 5, 2025 | markets.businessinsider.comB. Riley Forecasts Lineage Cell Therapeutics Q1 EarningsLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Equities researchers at B. Riley issued their Q1 2025 earnings per share estimates for shares of Lineage Cell Therapeutics in a note issued to investors on Thursday, March 13th. B. Riley analyst M. Mamtani expects that the companMarch 17, 2025 | marketbeat.comB. Riley Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock PriceB. Riley reduced their price target on Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a report on Friday.March 15, 2025 | marketbeat.comHC Wainwright Weighs in on Lineage Cell Therapeutics Q1 EarningsLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Lineage Cell Therapeutics in a report released on Tuesday, March 11th. HC Wainwright analyst J. Pantginis forecasts that the company will post earninMarch 14, 2025 | marketbeat.comBeyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics StockMarch 13, 2025 | nasdaq.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday.March 12, 2025 | marketbeat.comD. Boral Capital Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)D. Boral Capital reissued a "buy" rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday.March 12, 2025 | marketbeat.comLineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s PoliciesMarch 12, 2025 | tipranks.comLineage Cell Therapeutics’ Earnings Call: Progress Amid ChallengesMarch 11, 2025 | tipranks.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | insidermonkey.comLineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | seekingalpha.comLineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 10, 2025 | businesswire.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Short Interest UpdateLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 21,300,000 shares, a drop of 21.4% from the January 15th total of 27,110,000 shares. Based on an average trading volume of 2,560,000 shares, the days-to-cover ratio is presently 8.3 days.February 15, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday.February 11, 2025 | marketbeat.comLineage Initiates Clinical Study of OPC1 for Spinal Cord InjuryFebruary 11, 2025 | finance.yahoo.comLineage Cell Therapeutics initiates study of OPC1 for spinal injuryFebruary 11, 2025 | markets.businessinsider.comD. Boral Capital Has Lowered Expectations for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock PriceD. Boral Capital cut their target price on Lineage Cell Therapeutics from $3.00 to $2.00 and set a "buy" rating on the stock in a research note on Tuesday.February 11, 2025 | marketbeat.comLineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences ConferenceFebruary 4, 2025 | finance.yahoo.comInsiders Are Scooping Up These 5 Stocks NowFebruary 2, 2025 | 247wallst.comPromising Advancements in Cell Therapy: Lineage Cell Therapeutics Receives Buy Rating from Joseph PantginisJanuary 31, 2025 | markets.businessinsider.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research report on Friday.January 31, 2025 | marketbeat.comDefender Capital LLC. Increases Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)Defender Capital LLC. lifted its holdings in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 19.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,963,348 sharesJanuary 30, 2025 | marketbeat.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Sees Large Growth in Short InterestLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 26,030,000 shares, an increase of 13.5% from the December 15th total of 22,940,000 shares. Based on an average trading volume of 2,170,000 shares, the days-to-cover ratio is currently 12.0 days.January 18, 2025 | marketbeat.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given New $3.00 Price Target at Maxim GroupMaxim Group reduced their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday.January 10, 2025 | marketbeat.comLineage Cell Therapeutics Issues Letter to StockholdersJanuary 6, 2025 | finance.yahoo.comThe Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 ExpertsJanuary 4, 2025 | benzinga.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given "Buy" Rating at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a research report on Friday.January 3, 2025 | marketbeat.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1% - Here's What HappenedLineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Down 1% - Here's WhyDecember 28, 2024 | marketbeat.comLineage Cell Therapeutics, Inc. (LCTX.TA)December 10, 2024 | finance.yahoo.com Get Lineage Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address LCTX Media Mentions By Week LCTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LCTX News Sentiment▼0.121.02▲Average Medical News Sentiment LCTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LCTX Articles This Week▼51▲LCTX Articles Average Week Get Lineage Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ChromaDex News AnaptysBio News Iovance Biotherapeutics News Dianthus Therapeutics News Keros Therapeutics News Taysha Gene Therapies News AbCellera Biologics News GH Research News KalVista Pharmaceuticals News Curaleaf News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:LCTX) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LCTX Stock Free LCTX Stock Alerts